Skip to main content
Keros Therapeutics, Inc. logo

Keros Therapeutics, Inc. — Investor Relations & Filings

Ticker · KROS ISIN · US4923271013 US Professional, scientific and technical activities
Open in API
Filings indexed 478 across all filing types
Latest filing 2026-06-03 Declaration of Voting R…
Country US United States of America
Listing US KROS

About Keros Therapeutics, Inc.

https://www.kerostx.com/

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics. The company develops engineered protein therapeutics designed to address a wide range of disorders linked to dysfunctional signaling of the transforming growth factor-beta (TGF-β) superfamily of proteins. Its approach aims to selectively and potently modulate these signaling pathways to treat the underlying causes of various hematological and musculoskeletal diseases.

Recent filings

Filing Released Lang Actions
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K current report containing Item 5.07: Submission of Matters to a Vote of Security Holders. It details the final voting results for three proposals at the 2026 Annual Meeting of Stockholders. This matches the definition for Declaration of Voting Results & Voting Rights Announcements (DVA), which covers official vote results at shareholder meetings.
2026-06-03 English
8-K
Regulatory Filings Classification · 90% confidence The document is a Form 8-K current report filed under the Securities Exchange Act of 1934. It furnishes a press release under Item 7.01 (Regulation FD Disclosure) and includes no substantive financial statements or financial results. This type of SEC Form 8-K is a general regulatory announcement and does not fall under any specific categories like earnings release, board management change, or financial report. Therefore, it should be classified as a Regulatory Filing (RNS).
2026-06-01 English
10-Q
Interim / Quarterly Report Q1 2026
2026-05-14 English
8-K
Report Publication Announcement Classification · 85% confidence The document is a Form 8-K filing which simply states that a press release announcing quarterly results is attached as Exhibit 99.1 and does not itself contain substantive financial data. It is under 5,000 characters and is an announcement of the release of a report rather than the report itself. Under the “menu vs. meal” rule, this falls into Report Publication Announcement.
2026-05-14 English
ARS - Keros Therapeutics, Inc. (0001664710) (Filer)
Annual Report
2026-04-22 English
DEF 14A - Keros Therapeutics, Inc. (0001664710) (Filer)
Proxy Solicitation & Information Statement
2026-04-22 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.